An AstraZeneca logo on a buildingAstraZeneca is partnering with the University of Oxford to develop and test a COVID-19 vaccine. | Photo by Paul Ellis / AFP via Getty Images

A big vaccine trial halted this week after a participant experienced serious neurological symptoms. It was one of the first known bumps in the road for the highly touted vaccine candidate, which is being developed by AstraZeneca and the University of Oxford.

AstraZeneca said Saturday it had resumed phase three trials in the UK only, after receiving confirmation from the UK Medicines Health Regulatory Authority that it was safe to do so. The company said in a blog post it could not reveal any medical information, saying only that the “standard review process triggered a voluntary pause,” adding it was working with health authorities in other countries to determine when other clinical trials may resume.

Hitting pause on a promising…

Continue reading…